Gene Therapy · us
Buying Time Against Childhood Vision Loss: RDH12 Gene Therapy Cleared by FDA to Enter Clinical Trials
OPGx-RDH12 is expected to begin a Phase 1/2 trial in the fourth quarter of this year, aiming to deliver a functional gene into retinal photoreceptor cells. This step opens the way for testing in humans and will examine whether laboratory findings can translate into a treatment that protects vision.
For children who begin losing their vision at a young age, treatment research is also racing against disease progression. Opus Genetics announced on October 21 that OPGx-RDH12, its gene therapy for RDH12-related Leber congenital amaurosis, had received clearance from the U.S. Food and Drug Administration (FDA) to enter clinical development, taking the candidate therapy a step closer to testing in humans.
The company plans to begin a Phase 1/2 trial in the fourth quarter of 2026. However, clearance of an investigational new drug (IND) application means that clinical research can proceed. It does not mean the therapy has been approved for marketing, nor does it establish that the therapy can improve vision.
This type of inherited retinal disease results from variants in the RDH12 gene, and patients may experience progressive vision loss from early childhood. OPGx-RDH12 uses an adeno-associated virus (AAV) vector and is designed to deliver a functional copy of the RDH12 gene into retinal photoreceptor cells to compensate for impaired gene function.
According to the company's announcement, cell and mouse studies have shown restored RDH12 activity and functional improvements. However, the announcement did not provide complete data sufficient to assess the magnitude of the effects; whether these preclinical results can be replicated in humans remains a question for clinical trials.
Patient families are also helping drive development. The Global RDH12 Alliance, formed by the U.S.-based RDH12 Fund for Sight and the UK-based Eyes on the Future, contributes resources through collaboration and participates in clinical and regulatory strategy, bringing patient experience into the development process.
The next key questions are whether the trial can begin as planned and whether human data can support safety and benefits in visual function. The announcement has not yet specified enrollment numbers, the age range, or primary endpoints. What can currently be confirmed is that the research has reached a new regulatory milestone; how much vision the therapy can preserve and how long its effects may last remain to be established.